Updating results

99 results for dyspepsia Sort: Relevance | Date

Dyspepsia and gastro-oesophageal reflux disease

In this interactive flowchart infants are defined as under 1 year, children 1 to under 12 years, young people 12 to under 18 years and adults 18 years and older. Infants, children and young peopleGastro-oesophageal reflux is a normal physiological

NICE Pathway Published September 2014 Last updated March 2017

The clinical and cost effectiveness of proton pump inhibitors for the treatment of dyspepsia (TA7)

This guidance has been updated and replaced by gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management

Technology appraisal guidance Published July 2000 Withdrawn

Dyspepsia: Management of dyspepsia in adults in primary care (CG17)

This guidance has been updated and replaced by gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management

Clinical guideline Published August 2004 Withdrawn

Specialist investigation:- What specialist investigations should be conducted to exclude a diagnosis of functional dyspepsia in people with uninvestigated dyspepsia that does not respond to PPIs or H2 receptor antagonists (H2RAs) despite optimum primary care?

...conducted to exclude a diagnosis of functional dyspepsia in people with uninvestigated dyspepsia that does not respond to PPIs or H2 receptor...if applicable) People with uninvestigated dyspepsia that fails to respond to PPIs or H2RAs, despite...

Research recommendation Published June 2015

The way to medicines optimisation is through the stomach - tackling high prescribing levels using the NICE Dyspepsia guideline to review proton pump inhibitor (PPI) prescribing.

...Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management...Full title of NICE guidance: CG184 - Dyspepsia and gastro‑oesophageal reflux disease: Investigation and management of dyspepsia, symptoms suggestive of gastro & oesophageal...

Shared learning Published January 2013 Last updated April 2015

Suspected cancer recognition and referral

This interactive flowchart covers the recognition and selection for referral or investigation in primary care of people of all ages, including children (aged from birth to 15 years) and young people (aged 16 to 24), who may have cancer. Although the

NICE Pathway Published June 2015 Last updated March 2017

Head and neck cancer (QS146)

Evidence-based statements to deliver quality improvements in assessing, diagnosing and managing head and neck cancer in young people and adults

Quality standard Published March 2017

Dimethyl fumarate for treating relapsing‐remitting multiple sclerosis (TA320)

Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis (MS/RRMS)

Technology appraisal guidance Published August 2014

Coeliac disease: recognition, assessment and management (NG20)

Evidence-based recommendations on the recognition, assessment and management of coeliac disease in children, young people and adults.

NICE guideline Published September 2015

Coeliac disease

Coeliac disease is an autoimmune condition associated with chronic inflammation of the small intestine, which can lead to malabsorption of nutrients. Dietary proteins, known as glutens, which are present in wheat, barley and rye activate an abnormal

NICE Pathway Published October 2012 Last updated October 2016

Cerebral palsy in under 25s: assessment and management (NG62)

Evidence-based recommendations on diagnosing, assessing and managing cerebral palsy in children and young people under 25

NICE guideline Published January 2017

Osteoporosis (QS149)

Evidence-based statements to deliver quality improvements in managing osteoporosis in adults, including assessing risk and preventing fragility fractures

Quality standard Published April 2017

Non-Hodgkin’s lymphoma: diagnosis and management (NG52)

Evidence-based recommendations on diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over

NICE guideline Published July 2016

Heavy menstrual bleeding

This pathway covers heavy menstrual bleeding.Heavy menstrual bleeding is defined as excessive menstrual blood loss which interferes with a woman's physical, social, emotional and/or material quality of life. It can occur alone or in combination with

NICE Pathway Published February 2012 Last updated August 2016

Multimorbidity

Multimorbidity is usually defined as when a person has 2 or more long-term health conditions. This interactive flowchart covers the optimisation of care for: adults with 2 or more long-term physical health conditions adults with 1 or more mental

NICE Pathway Published September 2016 Last updated April 2017

Idiopathic pulmonary fibrosis

This pathway covers the diagnosis and management of suspected idiopathic pulmonary fibrosis in adults.Idiopathic pulmonary fibrosis is a chronic, progressive fibrotic interstitial lung disease of unknown origin. It is a difficult disease to diagnose

NICE Pathway Published June 2013 Last updated January 2016

Medicines optimisation

This interactive flowchart covers the decision-making processes to help optimise a person's medicines. The guidance is combined with recommendations from the medicines adherence guideline to demonstrate how this decision-making process supports

NICE Pathway Published March 2015 Last updated May 2017

Gastrointestinal conditions

This interactive flowchart includes recommendations on gastrointestinal conditions, including conditions of the oesophagus, stomach, small intestine, gallbladder, pancreas, large intestine, rectum and anus.

NICE Pathway Published November 2013 Last updated May 2017

Osteoporosis

This interactive flowchart covers NICE guidance on osteoporosis in people aged 18 and over, including assessing the risk of fragility fracture and drug treatment for the primary and secondary prevention of osteoporotic fragility fractures.

NICE Pathway Published August 2012 Last updated April 2017

Pirfenidone for treating idiopathic pulmonary fibrosis (TA282)

Evidence-based recommendations on pirfenidone (Esbriet) for treating idiopathic pulmonary fibrosis (IPF)

Technology appraisal guidance Published April 2013

Mirabegron for treating symptoms of overactive bladder (TA290)

Evidence-based recommendations on mirabegron (Betmiga) for treating the symptoms of overactive bladder

Technology appraisal guidance Published June 2013

Irritable bowel syndrome in adults: diagnosis and management (CG61)

Evidence-based recommendations on diagnosing and managing irritable bowel syndrome (IBS) in adults

Clinical guideline Published February 2008 Last updated April 2017

Smokeless tobacco: South Asian communities (PH39)

Evidence-based recommendations on the cessation of smokeless tobacco (including misri, qimam, naswar and gutkha) for people of South Asian origin

Public health guideline Published September 2012

Heavy menstrual bleeding: assessment and management (CG44)

Evidence-based recommendations on heavy menstrual bleeding (HMB)

Clinical guideline Published January 2007 Last updated August 2016

Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249)

Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in atrial fibrillation (AF)

Technology appraisal guidance Published March 2012

Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)

Evidence-based recommendations on alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of

Technology appraisal guidance Published October 2008 Last updated January 2011

Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)

Evidence-based recommendations on alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic

Technology appraisal guidance Published October 2008 Last updated January 2011

Idiopathic pulmonary fibrosis in adults: diagnosis and management (CG163)

Evidence-based recommendations on diagnosing and managing idiopathic pulmonary fibrosis (IPF) (hardening of the lungs) in adults

Clinical guideline Published June 2013 Last updated May 2017

Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (TA275)

Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (AF)

Technology appraisal guidance Published February 2013

Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256)

Evidence-based recommendations on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in atrial fibrillation (AF)

Technology appraisal guidance Published May 2012

Barrett's oesophagus: ablative therapy (CG106)

Evidence-based recommendations on care and treatment of adults having ablative therapy to treat Barrett’s oesophagus with high-grade dysplasia…

Clinical guideline Published August 2010

Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (CG68)

Evidence-based recommendations on the diagnosis and initial management of stroke and transient ischaemic attack (TIA or ‘mini-stroke’) in over 16s

Clinical guideline Published July 2008 Last updated March 2017

Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and preventing recurrent venous thromboembolism

Technology appraisal guidance Published June 2013